Tricking an ancient immune function to eradicate hepatocellular carcinoma.
The circulating apoptosis inhibitor of macrophage (AIM) protein performs differential preventive roles against liver steatosis and hepatocellular carcinoma (HCC) development. Since non-alcoholic fatty liver disease, which is known as a manifestation of metabolic syndrome, has been increasingly highlighted for its association with HCC, therapeutic application of AIM would open the door toward a new mode of treatment for modern hepatic diseases.
Laboratory of Molecular Biomedicine for Pathogenesis; Center for Disease Biology and Integrative Medicine; Faculty of Medicine; The University of Tokyo, and CREST; Japan Science and Technology Agency , Tokyo, Japan.
Toru
T
Miyazaki
Laboratory of Molecular Biomedicine for Pathogenesis; Center for Disease Biology and Integrative Medicine; Faculty of Medicine; The University of Tokyo, and CREST; Japan Science and Technology Agency , Tokyo, Japan.
Satoko
S
Arai
AIM; HCC; complement; endocytosis; liver steatosis